Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Aaron Kantoff Biography and Net Worth

Director of Centessa Pharmaceuticals

Mr. Aaron Kantoff is the Director of Centessa Pharmaceuticals.

What is Aaron Kantoff's net worth?: The estimated net worth of Aaron Kantoff is at least $759,845.34 as of October 24th, 2023. Mr. Kantoff owns 45,391 shares of Centessa Pharmaceuticals stock worth more than $759,845 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Kantoff may own. Learn More about Aaron Kantoff's net worth.
How do I contact Aaron Kantoff?: The corporate mailing address for Mr. Kantoff and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on Aaron Kantoff's contact information.
Has Aaron Kantoff been buying or selling shares of Centessa Pharmaceuticals?: Aaron Kantoff has not been actively trading shares of Centessa Pharmaceuticals in the last ninety days. Most recently, on Thursday, November 18th, Aaron Kantoff bought 10,000 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $11.98 per share, with a total value of $119,800.00. Learn More on Aaron Kantoff's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Aaron Kantoff (Director), and Saurabh Saha (CEO). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, insiders at the sold shares 12 times. They sold a total of 380,458 shares worth more than $5,855,386.13. The most recent insider tranaction occured on October, 25th when insider Gregory M Weinhoff sold 11,742 shares worth more than $180,591.96. Insiders at Centessa Pharmaceuticals own 11.6% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 10/25/2024.

Aaron Kantoff Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/18/2021	Buy	10,000	$11.98	$119,800.00

Aaron Kantoff Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $15.79

$15.79

50 Day Range

MA: $16.03

$15.04

$18.08

2 Week Range

Now: $15.79

$5.58

$18.74

Volume

849 shs

Average Volume

407,473 shs

Market Capitalization

$1.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

This company will win the AI race

From Porter & Company | Ad